نتایج جستجو برای: dual antiplatelet therapy

تعداد نتایج: 804061  

Journal: :American family physician 2010
Pierre Guy Chassot Carlo Marcucci Alain Delabays Donat R Spahn

Aspirin is recommended as a lifelong therapy that should never be interrupted for patients with cardiovascular dis- ease. Clopidogrel therapy is mandatory for six weeks after placement of bare-metal stents, three to six months after myocardial infarction, and at least 12 months after placement of drug-eluting stents. Because of the hypercoagulable state induced by surgery, early withdrawal of a...

Journal: :Journal of the American College of Cardiology 2013
Steven M Markowitz

Clear evidence supports the value of oral anticoagulation (OAC) with vitamin K antagonists in preventing stroke and thromboembolism in patients with atrial fibrillation (AF) who have well-established risk factors. For this indication, vitamin K antagonists have been shown to be superior to single or dual antiplatelet agents in reducing thromboembolic complications (1). Yet, up to 30% of patient...

Journal: :Circulation 2012
Marco Valgimigli Gianluca Campo Monia Monti Pascal Vranckx Gianfranco Percoco Carlo Tumscitz Fausto Castriota Federico Colombo Matteo Tebaldi Giuseppe Fucà Moh'd Kubbajeh Elisa Cangiano Monica Minarelli Antonella Scalone Caterina Cavazza Alice Frangione Marco Borghesi Jlenia Marchesini Giovanni Parrinello Roberto Ferrari

BACKGROUND The optimal duration of dual-antiplatelet therapy and the risk-benefit ratio for long-term dual-antiplatelet therapy after coronary stenting remain poorly defined. We evaluated the impact of up to 6 versus 24 months of dual-antiplatelet therapy in a broad all-comers patient population receiving a balanced proportion of Food and Drug Administration-approved drug-eluting or bare-metal ...

2009
Jang-Young Kim

Platelets play a central role in the pathogenesis of atherothrombosis. Thus, achieving platelet inhibition is an important part of managing patients that have experienced an atherothrombotic event. Dual antiplatelet therapy with clopidogrel plus aspirin has been shown to markedly reduce ischemic events in patients undergoing percutaneous coronary intervention (PCI) and stenting. Despite its pro...

2012
Marco Valgimigli Monia Monti Antonella Scalone

Background—The optimal duration of dual-antiplatelet therapy and the risk-benefit ratio for long-term dual-antiplatelet therapy after coronary stenting remain poorly defined. We evaluated the impact of up to 6 versus 24 months of dual-antiplatelet therapy in a broad all-comers patient population receiving a balanced proportion of Food and Drug Administration–approved drug-eluting or bare-metal ...

Journal: :The American journal of managed care 2009
Sarah A Spinler

Percutaneous coronary intervention (PCI) with stenting is increasingly being utilized for acute coronary syndromes (ACS), and the debate over the safety and efficacy of drug-eluting stents (DESs) versus bare-metal stents (BMSs) has intensified. The difficulty in consistently assessing stent safety is because of the widespread off-label use in patients with clinical features and coronary anatomy...

Journal: :European urology 2008
Fleur I de Korte Jochem W van Werkum Peter L M Vijverberg Jurriën M Ten Berg

The current practice of withdrawing antiplatelet therapy before major surgery has been challenged by the introduction of coronary drug-eluting stents (DESs) since evidence is accumulating that a DES requires dual antiplatelet therapy for at least a year. The authors present a case demonstrating difficulty in decision-making when it comes to appropriate perioperative antiplatelet therapy. The pa...

Journal: :Circulation 2012
Aldo Pietro Maggioni

What We Know Dual antiplatelet therapy is the recommended treatment for all patients with an acute coronary syndrome treated or not treated with an invasive procedure.1–4 Several trials testing clopidogrel5–7 or new antiplatelet agents8,9 clearly showed that the addition of a thyenopiridine to aspirin is associated with a significant improvement of patients’ outcomes. Furthermore, even in the c...

2018
Maria Noflatscher Nicolas Moes Eva-Maria Gassner Peter Marschang

Citation: Noflatscher M, Moes N, Gassner E-M and Marschang P (2018) Dabigatran Added to Dual Antiplatelet Therapy to Treat a Left Ventricular Thrombus in an 87 Year Old Patient With Myocardial Infarction and Very High Bleeding Risk. Front. Pharmacol. 9:217. doi: 10.3389/fphar.2018.00217 Dabigatran Added to Dual Antiplatelet Therapy to Treat a Left Ventricular Thrombus in an 87 Year Old Patient ...

2017
Ali Shafiq Javier Valle Jae-Sik Jang Mohammed Qintar Kensey Gosch David J. Cohen Mandeep Singh Richard Bach John A. Spertus

Variation in practice regarding pretreatment with dual antiplatelet therapy for patients with non–ST elevation myocardial infarction. Background-—Despite guideline recommendations, a significant number of patients with non–ST elevation myocardial infarction (NSTEMI) do not receive dual antiplatelet therapy (DAPT) before angiography " pretreatment. " While there may be valid clinical reasons to ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید